A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris

Journal of Dermatological Treatment

Volumn 15, Issue 2, 2004, Pages 98-103

  Torras, Helena ^a   Aliaga, A ^b   Lopez Estebaranz J L ^c,d   Hernandez I ^e   Gardeazabal, J ^f   Quintanilla, E ^g   Mascaro J M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Calcipotriol; Clinical trial; Comparative study; Photochemotherapy; Psorias; PUVA

Indexed keywords

CALCIPOTRIOL; METHOXSALEN; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PUVA; RADIATION DOSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SKIN MANIFESTATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADMINISTRATION, CUTANEOUS; ADULT; CALCITRIOL; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

EID: 1842663103     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630410023322     Document Type: Article

References (14)

1. Wolff K, Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol (1990) 122 (suppl 36): 117-25.
2. Stern RS, Nichols KT, Väkevä LH, Malignant melanoma in patients treated for psoriasis with methosalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med (1997) 336: 1041-5.
3. Lindelöf B, Risk of melanoma with psoralen/ultraviolet. A therapy for psoriasis. Do the known risks now outweigh the benefits?. Drug Safety (1999) 20: 289-97.
4. Frappaz A, Thivolet J, Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol (1993) 3: 351-4.
5. Kokelj F, Plozzer C, Torsello P, Reduction of UV-A radiation induced by calcipotriol in the treatment of vulgar psoriasis with oral psoralen plus UV-A. Arch Dermatol (1997) 133: 668-9.
6. Kragballe K, Beck HI, Soegaard H, Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-blind study. Br J Dermatol (1988) 119: 223-30.
7. Kragballe K, Barnes L, Hamberg KJ, Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol (1998) 139: 649-54.
8. Molin L, Cutler TP, Helander I et al. Comparative efficacy of calcipotriol (MC 903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. Calcipotriol study group. Br J Dermatol (1997) 136: 89-93.
9. Fredriksson T, Petterson U, Severe psoriasis - oral therapy with a new retinoid. Dermatologica (1978) 157: 238-44.
10. Parrish JA, Fitzpatrick TB, Tanenbaum L et al, Photochemotherapy of psoriasis with oral methoxsalen and long wave ultraviolet light. N Engl J Med (1974) 291: 1207-11.
11. Stern RS, Actinic degeneration and pigmentary change in association with psoralen and UVA treatment: a 20-year prospective study. J Am Acad Dermatol (2003) 48: 61-7.
12. Bruynzeel I, Bergman W, Hartevelt HM et al, 'High single-dose' European PUVA regimen also causes an excess of non-melanoma skin cancer. J Dermatol (1991) 124: 49-55.
13. Youn JI, Park BS, Park SB et al, Comparison of calcipotriol-PUVA with conventional PUVA in the treatment of psoriasis. J Dermatol Treat (2000) 11: 125-30.
14. Schiffner R, Schiffner-Rohe J, Gerstenhauer M et al, Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol (2001) 144: 1154-60.